Literature DB >> 20589973

Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload.

Koji Ito1, Yoshitaka Hirooka, Kenji Sunagawa.   

Abstract

OBJECTIVES: In a pressure overload model, sympathetic activity is augmented in response to salt intake. Mineralocorticoid receptors and epithelial Na channels (ENaCs) are thought to contribute to Na-processing, but the underlying mechanism is unknown. Here, we investigated the contribution of the brain mineralocorticoid receptor- ENaC pathway to salt-induced sympathetic activation in a pressure overload model. METHODS AND
RESULTS: Aortic banding was performed to produce a mouse pressure overload model. Four weeks after aortic banding (AB-4), left-ventricular (LV) wall thickness was increased without a change in percentage fractional shortening (%FS). Sympathetic activity increased in response to a 5-day high-salt diet in AB-4, but not in Sham-4. Brain mineralocorticoid receptor, alphaENaC, and angiotensin II type 1 receptor (AT1R) expression levels were greater in AB-4 than in Sham-4. The increase in sympathetic activity and in the expression of these proteins was blocked by intracerebroventricular (ICV) infusion of eplerenone, a mineralocorticoid receptor blocker. In another protocol, AB-4 mice were fed a high-salt diet (AB-H) for 4 additional weeks. At 4 weeks, %FS was decreased and sympathetic activity was increased in AB-H compared with Sham. Expression of mineralocorticoid receptors and AT1R in the brain was higher in AB-H than in Sham. ICV infusion of eplerenone in AB-H attenuated salt-induced sympathoexcitation and the decreased %FS. ICV infusion of eplerenone also decreased brain AT1R expression.
CONCLUSIONS: These findings indicate that activation of brain alphaENaC and AT1R through mineralocorticoid receptors contributes to the acquisition of Na sensitivity to induce sympathoexcitation. Therefore, high salt intake accelerates sympathetic activation and LV systolic dysfunction in a pressure overload model.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589973     DOI: 10.1097/hjh.0b013e328338bb37

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  Central neuromodulatory pathways regulating sympathetic activity in hypertension.

Authors:  Alexander Gabor; Frans H H Leenen
Journal:  J Appl Physiol (1985)       Date:  2012-07-05

Review 2.  The Role of CNS in the Effects of Salt on Blood Pressure.

Authors:  Megumi Fujita; Toshiro Fujita
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 3.  The role of CNS in salt-sensitive hypertension.

Authors:  Megumi Fujita; Toshiro Fujita
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

4.  Enhanced expression of epithelial sodium channels causes salt-induced hypertension in mice through inhibition of the α2-isoform of Na+, K+-ATPase.

Authors:  Frans H H Leenen; Xiaohong Hou; Hong-Wei Wang; Monir Ahmad
Journal:  Physiol Rep       Date:  2015-05

5.  Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats.

Authors:  Kento Kitada; Daisuke Nakano; Ya Liu; Yoshihide Fujisawa; Hirofumi Hitomi; Yuki Shibayama; Hirotaka Shibata; Yukiko Nagai; Hirohito Mori; Tsutomu Masaki; Hiroyuki Kobori; Akira Nishiyama
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

6.  Central mechanisms of abnormal sympathoexcitation in chronic heart failure.

Authors:  Takuya Kishi; Yoshitaka Hirooka
Journal:  Cardiol Res Pract       Date:  2012-08-07       Impact factor: 1.866

Review 7.  Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.

Authors:  S Takahashi; J Katada; H Daida; F Kitamura; K Yokoyama
Journal:  J Hum Hypertens       Date:  2015-12-17       Impact factor: 3.012

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.